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Background: Pseudomonas aeruginosa has been highly associated with carbapenem resistance in which 
carbapenemases has been suggested to be a major contributory factor. Hence the objective of this study was to 
phenotypically detect KPC-type carbapenemase, metallo-β-lactamase and OXA-48 carbapenemase production in 
clinical isolates of P. aeruginosa in Lagos University Teaching Hospital (LUTH), Nigeria  
Methodology: One hundred and seventy-one P. aeruginosa isolates consecutively recovered from clinical 
specimens of patients with infections at the Medical Microbiology and Parasitology laboratory of the hospital were 
identified using MicrobactTM 24E kit. Preliminary screening for carbapenem resistance was determined by the disc 
diffusion method on Mueller-Hinton agar using single discs of meropenem and imipenem. Phenotypic detection 
of carbapenemase production among carbapenem-resistant isolates was performed by the combination disc test 
of meropenem-phenylboronic acid (MRPBO) and meropenem-dipicolinic acid (MRPDP) as recommended by 
EUCAST 2013 guideline.  
Results: Out of the 171 P. aeruginosa isolates, 35 (20.5%) were carbapenem non-susceptible (resistant) while 
carbapenemase production was detected in 27 (77.1%) of these carbapenem resistant isolates, and no enzyme 
was detected in 8 (22.9%). Of the 27 carbapenemase producing isolates, 22 (81.5%) produced MBL, 1 (3.7%) 
produced KPC, while 4 (14.8%) produced both KPC and MBL enzymes.                    
Conclusion: This study revealed that carbapenem resistance among P. aeruginosa clinical isolates in our 
institution is gradually increasing. The mechanism for this rise is associated with carbapenemases, with MBL being 
the major carbapenemase involved. There is the need to ensure strict compliance with the LUTH infection control 
guidelines in order to check the rising incidence of infection caused by carbapenem resistant P. aeruginosa.  
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Abstrait: 
Contexte: Pseudomonas aeruginosa a été fortement associé à la résistance aux carbapénèmes dans laquelle les 
carbapénèmases ont été suggérées comme étant un facteur contributif majeur. Par conséquent, l'objectif de cette 
étude était de détecter phénotypiquement la production de carbapénémase de type KPC, de métallo-β-lactamase 
et de carbapénémase OXA-48 dans des isolats cliniques de P. aeruginosa au Lagos University Teaching Hospital 
(LUTH), Nigeria.                




Méthodologie: Cent soixante et onze isolats de P. aeruginosa récupérés consécutivement à partir d'échantillons 
cliniques de patients infectés au laboratoire de microbiologie médicale et de parasitologie de l'hôpital ont été 
identifiés à l'aide du kit MicrobactTM 24E. Le dépistage préliminaire de la résistance aux carbapénèmes a été 
déterminé par la méthode de diffusion sur disque sur gélose Mueller-Hinton en utilisant des disques uniques de 
méropénème et d'imipénème. La détection phénotypique de la production de carbapénèmes parmi les isolats 
résistants aux carbapénèmes a été réalisée par le test de disque combiné d'acide méropénème-phénylboronique 
(MRPBO) et d'acide méropénème-dipicolinique (MRPDP) tel que recommandé par la directive EUCAST 2013. 
Résultats: Sur les 171 isolats de P. aeruginosa, 35 (20,5%) étaient des carbapénèmes non sensibles (résistants) 
tandis que la production de carbapénèmes a été détectée dans 27 (77,1%) de ces isolats résistants aux 
carbapénèmes, et aucune enzyme n'a été détectée dans 8 (22,9%). Sur les 27 isolats producteurs de 
carbapénémases, 22 (81,5%) produisaient des MBL, 1 (3,7%) produisaient des KPC, tandis que 4 (14,8%) 
produisaient à la fois des enzymes KPC et MBL.                           
Conclusion: Cette étude a révélé que la résistance aux carbapénèmes parmi les isolats cliniques de P. aeruginosa 
dans notre institution augmente progressivement. Le mécanisme de cette augmentation est associé aux 
carbapénémases, la MBL étant la principale carbapénémase impliquée. Il est nécessaire de garantir le strict 
respect des directives de contrôle des infections LUTH afin de contrôler l'incidence croissante des infections 
causées par P. aeruginosa résistant aux carbapénèmes. 
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Introduction: 
 Pseudomonas aeruginosa is a member 
of the Gamma Proteobacteria class of bact- 
eria, a Gram-negative aerobic bacillus belon- 
ging to the family Pseudomonadaceae (1). 
Pseudomonas aeruginosa is associated with 
varying degree of infections ranging from            
mild to severe infections. These include otitis 
externa, urinary tract infection, lower respira- 
tory tract infections, folliculitis, keratitis, 
infection of corneal ulcers, endophthalmitis 
and opportunistic blood stream infection in 
immunocompromised patients. It is also an 
important cause of nosocomial infections            
such as ventilator-associated pneumonia and 
wound infections in burn patients, and causes 
damage to the lung tissue with decreased 
pulmonary function in patients with cystic 
fibrosis (2,3). Pseudomonas aeruginosa is 
rarely a part of the microbial flora of healthy 
individuals, but may colonize the gastro- 
intestinal tract of hospitalized patients, parti- 
cularly neutropenic patients who have rece- 
ived previous antibiotic therapy (3). Pseudo- 
monas aeruginosa is notoriously resistant to a 
number of antibiotics and only a handful of 
antibiotics are effective for treating infections 
caused by P. aeruginosa.      
 Carbapenems are class of beta-lactam 
antibiotics with a broad spectrum antibacte- 
rial activity. They are used in the treatment of 
severe infections caused by bacteria producing 
the extended-spectrum beta-lactamases (ES- 
BLs) or multi-drug resistant Pseudomonas spp 
overexpressing chromosomal AmpC β-lacta- 
mases (4). Carbapenems approved for clinical 
use includes imipenem, meropenem, erta- 
penem and doripenem (5). The widespread 
occurrence of community-acquired bacterial 
isolates producing ESBLs capable of hydro- 
lyzing almost all β-lactam antibiotics except 
the carbapenems (6), led to increased use of 
the carbapenems, which became very crucial 
for treating life-threatening infections that are 
often associated with modern medical techni- 
ques and practice such as transplantation, 
intensive care unit hospitalization and highly 
technical surgery (7). The subsequent emer- 
gence of carbapenem resistance has been 
largely associated with carbapenemase prod- 
uction. However, the actual prevalence of 
carbapenemase-producing bacterial strains 
remains unknown because many countries 
worldwide do not report rates of antibiotic 
susceptibility (8). 
 Carbapenemases are carbapenem-
hydrolyzing β-lactamases that are able to 
hydrolyze almost all β-lactams. Most are 
resilient against inhibition by commercially 
viable β-lactamase inhibitors (9). These 
enzymes are mostly of the Klebsiella pneu- 
moniae carbapenemase (KPC), Verona inte- 
gron-encoded metallo – β - lactamase (VIM), 
imipenemase (IMP), New Delhi metallo – β -
lactamase (NDM) and oxacillinase-48 (OXA-
48) types (10), which are enzymes in Ambler 
classes A, B, and D (9,11,12). The Ambler 
class A carbapenemases include the KPC 
(9,13,14), Serratia marcescens enzyme fam- 
ily (SME), imipenem-hydrolyzing β-lactamase 
(IMI), “Not metalloenzyme carbapenemase” 
(NMC) (9,11) and Guiana extended spectrum 
(GES) beta-lactamases (15). Although the 
KPC and GES β-lactamases are predomi- 
nantly found in Enterobacteriaceae, there 
have been reports of these enzymes in P. 
aeruginosa (16-19). The Ambler class B met- 
allo-β-lactamases (MBLs) include IMP, VIM-1, 
VIM-2, (20,21), NDM-1, GIM (22), and Seoul 
imipenemase (SIM) (23). However, VIM and 
IMP have been reported in P. aeruginosa (20). 
The Ambler class D serine-carbapene- mases 
include oxacillin-hydrolyzing (OXA) β-lacta- 
mases in which P. aeruginosa is one of the 
organisms where it has been mainly impli- 
cated (11,24).     
 There are various strategies that have 
been proposed for detection of carbapene- 
mases and the genes encoding them. A series 
of non-molecular tests have also been pro- 
posed for the detection of carbapenemase 




activity (7,25) such as the inhibitor-based 
method which depends on demonstrating 
synergy between an indicator carbapenem and 
various in-vitro β-lactamase inhibitors. MBL 
inhibitors include ethylenediamine tetra- 
acetic acid (EDTA) and dipicolinic acid (DPA), 
while inhibitors of KPC and other class A 
carbapenemases are boronic acids, usually 3-
aminophenylboronic acid (APBA) or phenyl- 
boronic acid (PBA), although the mechanism 
of inhibition is not known (26-32). There is no 
known specific inhibitor for OXA-48-like carba- 
penemases but the disc diffusion assay using 
temocillin besides PBA and DPA, is usually 
utilized since OXA-48 confers high-level temo- 
cillin resistance. The objective of this study is 
to determine the prevalence of phenotypic 
KPC, MBL and OXA-48 carbapenemases prod- 
uction in clinical isolates of P. aeruginosa in 
Lagos University Teaching Hospital, Nigeria 
Materials and method:  
Study setting  
 The study setting is Lagos University 
Teaching Hospital (LUTH), a 764-bed tertiary 
care hospital in Lagos, southwest region of 
Nigeria, which service covers the entire Lagos 
State and neighboring Ogun State.  
 
Study design, protocol and ethical approval 
 This is a laboratory-based study of 
171 P. aeruginosa isolates recovered by stan- 
dard microbiological methods consecutively 
from clinical specimens of patients with infec- 
tions, submitted to the Department of Medical 
Microbiology and Parasitology of the hospital 
between November 2014 and October 2015 
(33). The isolates were identified to species 
level using the commercial MicrobactTM 24E 
(Oxoid, UK) kit according to the manufac- 
turer’s instructions. The protocol for the study 
was approved by the Ethics Review committee 
of LUTH. Waiver of consent was approved and 
data were anonymized prior to analysis.  
 
Screening and phenotypic detection of carba- 
penemase production    
 Screening for carbapenem resistance 
was determined by disc diffusion method on 
Mueller-Hinton agar using commercially avai- 
lable single discs of meropenem and imi- 
penem (Oxoid, England, UK) (34). All isolates 
with zone diameter of inhibition less than the 
cut-off values for imipenem (<23mm) and/or 
meropenem (<25mm) (carbapenem resis- 
tant) were tested for phenotypic production of 
carbapenemases using the EUCAST 2013 
guidelines (35). Phenotypic detection of carb- 
apenemase production was performed by the 
combination disc test using commercially avai- 
lable tablets (Rosco Diagnostica Neo-Sensi- 
tabs, Rosco, Taastrup, Denmark) (36-37). The 
KPC/MBL in P. aeruginosa Confirm Kit version 
2 (98025) was used for testing according to 
the manufacturer’s instructions.  
 The test was carried out on Mueller 
Hinton agar using the modified Kirby-Bauer 
method and EUCAST disk diffusion method 
2013 version 3.0 (35). Few morphologically 
similar colonies of overnight pure culture 
isolates were inoculated into sterile normal 
saline and visible turbidity was adjusted to 
match the turbidity of 0.5 McFarland stan- 
dards. The inoculum suspension was streaked 
onto Mueller-Hinton agar plate using a sterile 
swab stick. Tablets containing Meropenem 
10µg (MRP10), Meropenem 10µg + Phenyl- 
boronic acid (MRPBO) and Meropenem 10µg + 
Dipicolinic acid (MRPDP) were applied and 
incubation was done at 35±1°C for 16-20 
hours. The zone diameter of inhibition of each 
isolate to the tablets was measured using a 
calibrated ruler, and result inter- preted using 
the EUCAST guideline.  
 When the zones of inhibition of 
MRP10, MRPBO and MRPDP were within 2mm 
of each other, the isolate was reported as not 
producing KPC and MBL. When the MRPBO 
showed a zone difference of ≥ 4mm from 
MRP10, the isolate was reported as demon- 
strating KPC activity. When MRPDP showed a 
zone difference of ≥5mm from MRP10, the 
isolate was reported as demonstrating Metal- 
lo-β-lactamase activity. Only ceftazidime res- 
istant isolates were tested, as false positive 
MBL may be obtained with ceftazidime sensi- 




 A total of 171 P. aeruginosa were tes- 
ted for carbapenem resistance and subse- 
quently tested for carbapenemase production. 
The isolates were recovered from patients with 
sepsis (n=3), ocular infections (n=5), oto- 
laryngeal infections (n=22), chest infections 
(n=7), intra-abdominal infections (n=2), rep- 
roductive system infections (n=3), bone/joint 
infections (n=5), urinary tract infections (n= 
39), surgical site infections (n=16) and wound 
infections (n=69) (Table 1). 
 A total of 35 (20.5%) isolates were 
carbapenem non-susceptible (resistant) while 
carbapenemase production was detected in 27 
(77.1%), and no enzyme was detected in 8 
(22.9%) of the carbapenem resistant isolates. 
Of the 27 carbapenemase producing isolates, 
22 (81.5%) produced MBL, 1 (3.7%) produced 
KPC, and 4 (14.8%) produced both KPC and 
MBL enzymes (Table 2). 
Discussion: 
 In this study, the prevalence of carba- 
penem resistance among clinical isolates of P. 
aeruginosa in our institution was 20.5%. This 




is similar to the findings in Turkey and India 
where the prevalence of carbapenem resistant 
P. aeruginosa was 20% (38) and 18.2% (39) 
respectively. This rate is quite high for a drug 
which is usually reserved for last resort use. 
Previous studies carried out in our institution 
reported prevalence rates of carbapenem 
resistance among Pseudomonas isolates to be 
4.1% in 2007 (40) and 5.9% in 2013 (33). 
Comparing the results of the two studies to 
this present one indicates that the prevalence 
of carbapenem resistance among P. aerug- 
inosa isolates in our institution is increasing. 
 Carbapenemase production is the 
most predominant mechanism that confers 
clinically significant resistance to Gram-nega- 
tive bacteria (GNB) (41-45), which is why 
most carbapenem-resistant P. aeruginosa iso- 
lates in our study (77.1%) produced carba- 
penemases. This high rate of carbapenemase 
production was also reported by Ogbolu et al., 
(46) with a rate of 59.7% and by Mohammed 
et al., (47) with a rate of 82.1% in other 
institutions in Nigeria. Also, a study conducted 
in India (39) using two different types of 
phenotypic testing methods reported a high 
rate of carbapenemase production of  93.1% 
(combined disk synergy test) and 87.2% 
(double-disk synergy test). It should be noted 
that 22.9% of the carbapenem resistant P. 
aeruginosa isolates in this study did not 
produce carbapenemase, which suggests that 
other resistance mechanisms such as over- 
production of AmpC cephalosporinase, drug 
efflux, and deficient production or loss of 
porins might be responsible for the carba- 
penem resistance in these isolates (48).
 The most common  carbapenemases 
produced by P. aeruginosa in this study were 
MBLs (81.5%) and KPC (3.7 %), which is 
similar to the findings of Mushi et al., (49) in 
Tanzania, whereas KPC was reported to be 
more common than MBL by Vanegas et al., 
(50) in Colombia.  
 
 
Table 1: Distribution of Pseudomonas aeruginosa isolates from different infection sites in Lagos University 
Teaching Hospital, Nigeria 
Types of infection  Frequency of P. 
aeruginosa 
Percentage 
Sepsis/Bacteraemia  3 1.8 
Eye infections 5 2.9 
Otolaryngeal infections  22 12.9 
Chest infections  7 4.1 
Intra-abdominal infections  2 1.2 
Reproductive system infections  3 1.8 
Bone/Joint infections  5 2.9 
Urinary tract infections  39 22.8 
Surgical site infections  16 9.4 
Wound infections  69 40.4 
Total 171 100 
 
 
Table 2:  Carbapenem resistant Pseudomonas aeruginosa and the carbapenemase types produced 
Carbapenemase types Frequency (%) 
MBL 
KPC 






Total 35 (100) 
KPC = Klebsiella pneumoniae carbapenemase; MBL = metallo-β-lactamase         
   




 The KPC/MBL confirmation kit used in 
this study could not detect OXA-48 enzyme. A 
more recent phenotypic detection method 
such as the carbapenem inactivation method 
(CIM) which detects KPC, MBL and OXA-48 
enzymes, may have detected the OXA-48 
enzymes if used in this study. However, this 
method was not available to us at the time of 
this study. Similarly, molecular methods which 
are reported to be more sensitive and specific 
in detecting KPC, MBL and OXA-48 genes, 
were not available for this study.  
Conclusion: 
 In conclusion, our findings revealed 
that carbapenem resistance among P.  aerug- 
inosa clinical isolates in our institution, is 
gradually on the rise, with carbapenemases 
being the major contributory mechanism for 
this, which is line with previous studies in this 
institution. Also, it is noteworthy to empha- 
size that P. aeruginosa can produce more than 
one class of carbapenemases as reported in 
our study, which raises some concern. Our 
findings also have serious implication for anti- 
microbial therapy of P. aeruginosa infections 
and infection control measures in our environ- 
ment, in view of the fact that new antibiotics 
are not forthcoming. Hence, the need to pre- 
serve the antibiotics we have now by embra- 
cing antimicrobial stewardship.   
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